Rob started with AstraZeneca in 2002 as a synthetic chemist in the Infection iMed. As a chemist, he was always trying to help connect people across lab spaces, project teams, worldwide sites, and business areas. In 2014 he went on a secondment into the Business Engagement group, whose remit was to support collaboration across the enterprise. This role fit so well, he never left! His first project was to deliver DocuSign to the business as a “Business As Usual; Software as a Service” to as many users as possible. This involved working with diverse teams across the globe including: privacy, security, legal, quality, service delivery, and more! After introduction of the core platform, the team also evaluated and validated the Part 11 (regulated) module. Over the last few years, AstraZeneca has doubled its DocuSign usage year after year (>120,000 transactions in 2016) and rapidly expanded its to over 200 diverse use cases across multiple business areas. We have also enabled it on a global scale, and have achieved at least one signature in 110 different countries. Please come listen to our journey so far, and see what AstraZeneca is planning for the future of DocuSign. On a personal note; while passionate about work pursuits, his true loves are technical rock climbing, skiing, and mountain biking.
Organization Name | Title At Company | Start Date | End Date | |
---|---|---|---|---|
AstraZeneca | Innovation Consultant | Sep 1, 2019 | — | Detail |